Disease severity prognostication in primary sclerosing cholangitis: a validation of the Anali scores and comparison with the potential functional stricture - Takeaways - MDSpire

Disease severity prognostication in primary sclerosing cholangitis: a validation of the Anali scores and comparison with the potential functional stricture

  • By

  • Sarah Poetter-Lang

  • Ahmed Ba-Ssalamah

  • Alina Messner

  • Nina Bastati

  • Raphael Ambros

  • Antonia Kristic

  • Jakob Kittinger

  • Svitlana Pochepnia

  • Sami A. Ba-Ssalamah

  • Jacqueline. C. Hodge

  • Emina Halilbasic

  • Sudhakar K. Venkatesh

  • Nikolaos Kartalis

  • Kristina Ringe

  • Lionel Arrivé

  • Michael Trauner

  • June 13, 2024

  • 0 min

Share

  • 1

    Primary sclerosing cholangitis (PSC) is a chronic inflammatory disease that requires non-invasive imaging for diagnosis and monitoring.

  • 2

    The Anali scoring system predicts PSC survival factors, including liver decompensation and the need for liver transplantation.

  • 3

    Gadoxetic acid-enhanced MRI (GA-MRI) effectively diagnoses potential functional strictures in PSC patients and predicts clinical outcomes.

  • 4

    Validation studies confirm the predictive value of Anali scores and their correlation with clinical outcomes in PSC patients.

  • 5

    A retrospective study included adults with large-duct PSC who underwent GA-MRI, excluding patients with confounding conditions.

Original Source(s)

Disease severity prognostication in primary sclerosing cholangitis: a validation of the Anali scores and comparison with the potential functional stricture

  • by Sarah Poetter-Lang, Ahmed Ba-Ssalamah, Alina Messner, Nina Bastati, Raphael Ambros, Antonia Kristic, Jakob Kittinger, Svitlana Pochepnia, Sami A. Ba-Ssalamah, Jacqueline. C. Hodge, Emina Halilbasic, Sudhakar K. Venkatesh, Nikolaos Kartalis, Kristina Ringe, Lionel Arrivé, Michael Trauner

  • June 13, 2024

Related Content

Correlation of histologic, imaging, and artificial intelligence features in NAFLD patients, derived from Gd-EOB-DTPA-enhanced MRI: a proof-of-concept study

FDA Approves Device for Pancreas Care

In the phase 3 PANOVA-3 trial, adding Tumor Treating Fields therapy to gemcitabine and nab-paclitaxel was associated with improved overall survival and delayed pain progression in adults with locally advanced pancreatic cancer.

Combination of quantitative MRI and laboratory markers for the detection and staging of metabolic dysfunction-associated steatotic liver disease